专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016115482A1 PHOSPHOGLYCERATE KINASE 1 (PGK) PROMOTERS AND METHODS OF USE FOR EXPRESSING CHIMERIC ANTIGEN RECEPTOR 审中-公开
标题翻译：磷酸激酶激酶1（PGK）促进剂及其用于表达CHIMERIC抗原受体的方法
公开(公告)号：WO2016115482A1
公开(公告)日：2016-07-21
申请号：PCT/US2016/013637
申请日：2016-01-15
申请人： NOVARTIS PHARMA AG , NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. , CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH , THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , BROGDON, Jennifer , EBERSBACH, Hilmar, Erhard , GLASS, David , HUBER, Thomas , JASCUR, Julia , JUNE, Carl, H. , LEE, Jihyun , MANNICK, Joan , MILONE, Michael, C. , MURPHY, Leon , POSEY, Avery, D. , SONG, Huijuan , WANG, Yongqiang , WEI, Lai , WU, Qilong , YANG, Qiumei , ZHANG, Jiquan
发明人： BROGDON, Jennifer , EBERSBACH, Hilmar, Erhard , GLASS, David , HUBER, Thomas , JASCUR, Julia , JUNE, Carl, H. , LEE, Jihyun , MANNICK, Joan , MILONE, Michael, C. , MURPHY, Leon , POSEY, Avery, D. , SONG, Huijuan , WANG, Yongqiang , WEI, Lai , WU, Qilong , YANG, Qiumei , ZHANG, Jiquan
IPC分类号： C07K14/705 , A61K35/17 , C07K16/28
CPC分类号： C07K16/2863 , A61K35/17 , A61K48/0058 , A61K2035/124 , A61P35/00 , A61P35/02 , C07K14/705 , C07K14/7051 , C07K14/70521 , C07K16/28 , C07K16/30 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N15/86 , C12N2740/10043 , C12N2740/15043 , C12N2800/60
摘要： The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.
摘要翻译：本发明提供用于治疗与本文所述的肿瘤抗原表达相关的疾病的组合物和方法。本发明还涉及包含与本文所述的肿瘤抗原特异性的嵌合抗原受体（CAR）可操作地连接的截短的PGK启动子的核酸，以及编码本发明的载体的重组T细胞和包含本发明的CAR的重组T细胞。本发明还包括施用表达CAR的遗传修饰的T细胞的方法，其包含如本文所述结合肿瘤抗原的抗原结合结构域。

2. 发明申请

WO2016014576A1 TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR 审中-公开
标题翻译：使用CD33基因抗原受体治疗癌症
公开(公告)号：WO2016014576A1
公开(公告)日：2016-01-28
申请号：PCT/US2015/041390
申请日：2015-07-21
申请人： NOVARTIS AG , THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , BROGDON, Jennifer , EBERSBACH, Hilmar , GILL, Saar , GLASS, David , HUBER, Thomas , JASCUR, Julia , KENDERIAN, Saad , MANNICK, Joan , MILONE, Michael, C. , MURPHY, Leon , RICHARDSON, Celeste , SINGH, Reshma , SONG, Huijuan , WU, Qilong , ZHANG, Jiquan
发明人： BROGDON, Jennifer , EBERSBACH, Hilmar , GILL, Saar , GLASS, David , HUBER, Thomas , JASCUR, Julia , KENDERIAN, Saad , MANNICK, Joan , MILONE, Michael, C. , MURPHY, Leon , RICHARDSON, Celeste , SINGH, Reshma , SONG, Huijuan , WU, Qilong , ZHANG, Jiquan
IPC分类号： C07K16/28 , C07K16/30 , C07K14/725 , C07K14/705 , A61K39/395 , A61K31/436 , A61K35/17 , A61P35/02
CPC分类号： C07K16/2851 , A61K31/436 , A61K31/711 , A61K35/28 , A61K38/00 , A61K38/1774 , A61K38/1793 , A61K39/39558 , A61K45/06 , A61K48/00 , A61K2039/505 , A61K2039/5156 , C07K14/7051 , C07K14/70517 , C07K14/7056 , C07K14/70578 , C07K14/7151 , C07K16/2803 , C07K16/30 , C07K16/3061 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C07K2319/03 , C07K2319/33 , C07K2319/70 , A61K2300/00
摘要： The disclosure provides compositions and methods for treating diseases associated with expression of CD33. The disclosure also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The disclosure also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
摘要翻译：本公开提供了用于治疗与CD33表达相关的疾病的组合物和方法。本公开还涉及对CD33特异性的嵌合抗原受体（CAR），编码它的载体和包含CD33 CAR的重组T细胞。本公开还包括施用表达包含CD33结合结构域的CAR的遗传修饰的T细胞的方法。

3. 发明申请

WO2016014565A2 TREATMENT OF CANCER USING HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR 审中-公开
标题翻译：用人源化抗BCMA嵌合抗原受体治疗癌症
公开(公告)号：WO2016014565A2
公开(公告)日：2016-01-28
申请号：PCT/US2015041378
申请日：2015-07-21
申请人： NOVARTIS AG , UNIV PENNSYLVANIA , BROGDON JENNIFER , CHOI EUGENE , EBERSBACH HILMAR , GLASS DAVID , HUET HEATHER , JUNE CARL H , MANNICK JOAN , MILONE MICHAEL C , MURPHY LEON , PLESA GABRIELA , RICHARDSON CELESTE , RUELLA MARCO , SINGH RESHMA , WANG YONGQIANG , WU QILONG
发明人： BROGDON JENNIFER , CHOI EUGENE , EBERSBACH HILMAR , GLASS DAVID , HUET HEATHER , JUNE CARL H , MANNICK JOAN , MILONE MICHAEL C , MURPHY LEON , PLESA GABRIELA , RICHARDSON CELESTE , RUELLA MARCO , SINGH RESHMA , WANG YONGQIANG , WU QILONG
IPC分类号： C07K16/28
CPC分类号： C07K14/705 , A61K35/12 , A61K38/177 , C07K16/2878 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2317/92 , C07K2319/00 , C07K2319/30
摘要： The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
摘要翻译：本发明提供了用于治疗与BCMA表达相关的疾病的组合物和方法。本发明还涉及对编码BCMA载体的BCMA载体特异性的嵌合抗原受体（CAR）和包含BCMA CAR的重组T细胞。本发明还包括施用表达包含BCMA结合结构域的CAR的遗传修饰的T细胞的方法。

4. 发明申请

WO2015020960A1 NOVEL LNCRNA POLYNUCLEOTIDES 审中-公开
标题翻译：新的LNCRNA多核苷酸
公开(公告)号：WO2015020960A1
公开(公告)日：2015-02-12
申请号：PCT/US2014/049611
申请日：2014-08-04
申请人： NOVARTIS AG , GLASS, David Jonathan , GONG, Chenguang , LI, Zhizhong
发明人： GLASS, David Jonathan , GONG, Chenguang , LI, Zhizhong
IPC分类号： C12N15/113 , A61K31/7088 , A61P35/00
CPC分类号： C12N15/113 , C12N15/11 , C12N2310/14
摘要： The present disclosure relates generally to LncMyoD, a LncRNA located in the human, about 22 kb upstream of (5' to) the MyoD gene, and located in the mouse about 30 kb upstream of the MyoD gene. The disclosure particularly pertains to compositions comprising the LncMyoD or a LncMyoD-derived polynucleotide, such as a pharmaceutical composition. LncMyoD-derived polynucleotides include polynucleotides comprising a portion of the LncMyoD sequence, such as one or more exons, one or more ORFs, one or more CAUH sequences, one or more fragments or portions, etc. The disclosure also pertains to methods of use of LncMyoD or a LncMyoD-derived polynucleotide in increasing muscle growth, treating sarcoma, treating other cancers in settings where IMP1 and/or IMP2 are upregulated, and/or in altering expression of other genes, such as c-Myc.
摘要翻译：本公开一般涉及位于人中的LncMyoD，位于MyoD基因（5'至上游）约22kb的LncRNA，位于MyoD基因上游约30kb的小鼠中。本公开特别涉及包含LncMyoD或LncMyoD衍生的多核苷酸（例如药物组合物）的组合物。 LncMyoD衍生的多核苷酸包括包含LncMyoD序列的一部分，例如一个或多个外显子，一个或多个ORF，一个或多个CAUH序列，一个或多个片段或部分等的多核苷酸。本公开还涉及使用 LncMyoD或LncMyoD衍生的多核苷酸，其中增加肌肉生长，治疗肉瘤，在IMP1和/或IMP2被上调的环境中治疗其它癌症，和/或改变其他基因如c-Myc的表达。

5. 发明申请

WO2011098449A1 METHODS AND COMPOUNDS FOR MUSCLE GROWTH 审中-公开
标题翻译：肌肉生长的方法和化合物
公开(公告)号：WO2011098449A1
公开(公告)日：2011-08-18
申请号：PCT/EP2011/051825
申请日：2011-02-08
申请人： NOVARTIS AG , GLASS, David , SHI, Jun
发明人： GLASS, David , SHI, Jun
IPC分类号： G01N33/68
CPC分类号： G01N33/6887 , G01N2333/4703 , G01N2500/04 , G01N2800/10
摘要： The disclosure relates to treating muscle wasting-associated disorders in a patient, using a therapeutically effective amount of an antagonist of Fbxo40, wherein the antagonist reduces the expression, level or activity of Fbxo40. The Fbxo40 antagonist increases muscle mass, or prevents, limits or reduces muscle mass loss, in the patient. The Fbxo40 antagonist can be a low molecular weight (LMW) compound, a protein, an antibody, or an inhibitory nucleic acid, such as a siRNA. The disclosure also relates to methods of screening for antagonists of Fbxo40, and methods of diagnosing or monitoring levels of muscle mass maintenance, loss or increase.
摘要翻译：本公开涉及使用治疗有效量的Fbxo40拮抗剂治疗患者中的肌肉消瘦相关疾病，其中拮抗剂降低Fbxo40的表达，水平或活性。 Fbxo40拮抗剂在患者体内增加肌肉质量，或防止，限制或减少肌肉质量损失。 Fbxo40拮抗剂可以是低分子量（LMW）化合物，蛋白质，抗体或抑制性核酸，例如siRNA。本公开还涉及筛选Fbxo40的拮抗剂的方法，以及诊断或监测肌肉质量维持，损失或增加水平的方法。

6. 发明申请

WO2008021547A3 DUAL MODE SERVICE WIFI ACCESS CONTROL 审中-公开
标题翻译：双模式服务WIFI访问控制
公开(公告)号：WO2008021547A3
公开(公告)日：2008-06-19
申请号：PCT/US2007018384
申请日：2007-08-17
申请人： AT & T MOBILITY II LLC , GLASS DAVID , ABU-DAYYA ADNAN
发明人： GLASS DAVID , ABU-DAYYA ADNAN
IPC分类号： H04M3/00
CPC分类号： H04W4/04 , H04L67/306 , H04L67/32 , H04M7/006 , H04W4/22 , H04W8/18 , H04W8/26 , H04W8/265 , H04W12/08 , H04W60/005 , H04W64/00 , H04W76/007 , H04W84/12 , H04W88/06 , H04W88/08
摘要： Systems and methods are described that facilitate the provision of dual mode services. Access to the dual mode services is controlled by associating a mobile device to an access point. Subscribers are required to provide valid geographical addresses for access points associated with the mobile devices prior to provision of service. Consequently, physical addresses are necessarily available for emergency services (e.g., E911). Mobile devices are restricted to specific access points based upon the access point identifiers automatically provided during initialization of service and maintained for authorization purposes.
摘要翻译：描述了有助于提供双模式服务的系统和方法。通过将移动设备关联到接入点来控制对双模式服务的访问。在提供服务之前，用户需要为与移动设备相关的接入点提供有效的地理地址。因此，物理地址必定可用于紧急服务（例如E911）。基于在服务初始化期间自动提供的接入点标识符并将其维护用于授权目的，移动设备被限制于特定的接入点。

7. 发明申请

WO2007146689A2 STABILIZED INSULIN-LIKE GROWTH FACTOR POLYPEPTIDES 审中-公开
标题翻译：稳定的胰岛素样生长因子多肽
公开(公告)号：WO2007146689A2
公开(公告)日：2007-12-21
申请号：PCT/US2007070468
申请日：2007-06-06
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , GLASS DAVID JONATHAN , FORNARO MARA
发明人： GLASS DAVID JONATHAN , FORNARO MARA
IPC分类号： C07K14/65
CPC分类号： C07K14/475 , A61K38/30 , C07K14/65
摘要： The invention relates to stabilized polypeptides having an IGF-1 or IGF-2 sequence and an E-peptide sequence, where the natural physiological cleavage of the E-peptide from the IGF is prevented.
摘要翻译：本发明涉及具有IGF-1或IGF-2序列和E肽序列的稳定的多肽，其中预防了来自IGF的E肽的天然生理切割。

8. 发明申请

WO2005033134A2 SECRETED PROTEIN THERAPEUTICS AND USES THEREOF 审中-公开
标题翻译：秘密蛋白质治疗药物及其用途
公开(公告)号：WO2005033134A2
公开(公告)日：2005-04-14
申请号：PCT/US2004/032233
申请日：2004-09-30
申请人： REGENERON PHARMACEUTICALS, INC. , GLASS, David, J.
发明人： GLASS, David, J.
IPC分类号： C07K14/47
CPC分类号： C07K14/65 , A61K38/00 , C07K14/475 , C07K14/705 , C07K14/70571 , C07K2319/02 , C07K2319/33 , C07K2319/73 , C07K2319/74 , C12N15/62
摘要： A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a multimerizing component and/or (iv) a signal sequence. In a preferred embodiment, the targeting fusion polypeptide targets muscle and is useful to treat a muscle-related disease or condition, such as muscle atrophy.
摘要翻译：（i）配体或其衍生物或片段与预先选择的目标表面蛋白（如受体）结合的组分，和（ii）活性剂或治疗剂，并且进一步任选地（iii）多聚化组分和/或（iv）信号序列。在一个优选的实施方案中，靶向融合多肽靶向肌肉并可用于治疗肌肉相关疾病或病症，例如肌肉萎缩。

9. 发明申请

WO1997027028A1 MULTIPLE CAGE GRINDING DEVICE 审中-公开
标题翻译：多槽式研磨装置
公开(公告)号：WO1997027028A1
公开(公告)日：1997-07-31
申请号：PCT/US1997001079
申请日：1997-01-27
申请人： CONSTANT VELOCITY SYSTEMS, INC. , NAUMANN, John, O. , GLASS, David, R.
发明人： CONSTANT VELOCITY SYSTEMS, INC.
IPC分类号： B24B49/00
CPC分类号： B24B19/02 , B24D7/18
摘要： A grinding machine (10) for several ball cages (132). The machine (10) contains a grinding bit (140), a multiple cage holder (20) in which several cages (132) are disposed so that the centers of the windows (212) of the cages are vertically aligned with each other, a device (84) for moving the multiple cage holder (20) in the z axis, the x axis, clockwise, and counterclockwise, a lubricating fluid injection system, and a high speed spindle (22).
摘要翻译：一种用于多个球笼（132）的磨床（10）。机器（10）包括研磨钻头（140），多保持器保持器（20），其中设置有多个保持架（132），使得保持架的窗口（212）的中心彼此垂直对准，装置（84），用于沿z轴，x轴，顺时针和逆时针方向移动多个保持架（20），润滑流体喷射系统和高速主轴（22）。

10. 发明申请

WO2016090034A2 METHODS FOR B CELL PRECONDITIONING IN CAR THERAPY 审中-公开
标题翻译：方法B细胞预处理在汽车治疗
公开(公告)号：WO2016090034A2
公开(公告)日：2016-06-09
申请号：PCT/US2015/063498
申请日：2015-12-02
申请人： NOVARTIS AG , THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , BROGDON, Jennifer , BEATTY, Gregory , GLASS, David , JUNE, Carl, H. , MANNICK, Joan , MILONE, Michael, C. , MURPHY, Leon , PLESA, Gabriela , SONG, Huijuan , WU, Qilong
发明人： BROGDON, Jennifer , BEATTY, Gregory , GLASS, David , JUNE, Carl, H. , MANNICK, Joan , MILONE, Michael, C. , MURPHY, Leon , PLESA, Gabriela , SONG, Huijuan , WU, Qilong
IPC分类号： C07K16/28 , A61K35/00 , C07K14/725 , C07K16/30 , C07K19/00 , A61P35/00
CPC分类号： C07K16/30 , A61K35/00 , A61K2039/5156 , A61K2039/5158 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K16/2803 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C07K2319/03 , C07K2319/33 , C07K2319/70
摘要： The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to the methods of preconditioning a subject, e.g., by depleting B cells in combination with the use of a cell comprising a chimeric antigen receptor (CAR) that targets a tumor antigen as described herein. The methods for preconditioning the subject described herein include using a cell comprising a CAR that targets a B cell antigen as described herein.
摘要翻译：本发明提供用于治疗与本文所述的肿瘤抗原表达相关的疾病的组合物和方法。本发明还涉及预处理受试者的方法，例如通过消耗B细胞与包含靶向本文所述的肿瘤抗原的嵌合抗原受体（CAR）的细胞的组合。用于预处理本文所述受试者的方法包括使用如本文所述的包含靶向B细胞抗原的CAR的细胞。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式